You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handouts:

How to Safely Take Your Oral Anti-Cancer Medication

How to Safely Handle Cancer Medications and Body Fluids at Home

Displaying Drugs List

175 Items
Other Name(s): Verzenio™
Jul 2020
Other Name(s): Zytiga®
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, according to specific criteria
Aug 2021
Other Name(s): Calquence®
Jul 2021
Other Name(s): Giotrif®
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
May 2021
Other Name(s): Proleukin® (interleukin-2)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
Jun 2019
Other Name(s): Alecensaro™
Funding:
Exceptional Access Program
  • Treatment of non-small cell lung cancer according to clinical criteria
May 2021
Other Name(s): MabCampath®
Sep 2019
Other Name(s): Piqray®
Jul 2021
Other Name(s): AMSA P D® (Erfa)
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Jul 2017
Other Name(s): Arimidex®
Funding:
ODB - General Benefit
  • anastrozole
Mar 2021
Other Name(s): Erleada®
Funding:
Exceptional Access Program
  • apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Updated
Sep 2021